

January 10, 2023

Dear Rett Patient Advocacy Leaders,

We are writing to provide updates about the REVEAL Pediatric Study which were issued in a press release today.

- The first pediatric patient was dosed with the investigational gene therapy in the United States (U.S.).
- The Medicines and Healthcare products Regulatory Agency (MHRA) authorized a clinical trial application to expand the ongoing U.S. REVEAL Pediatric Study in the United Kingdom (UK).

Below is a list of frequently asked questions about the REVEAL Pediatric Study.

**What is the REVEAL Pediatric Study?**

- The REVEAL Pediatric Study is a Phase 1/2 study designed to evaluate whether TSHA-102, the investigational gene therapy, is safe, whether it is tolerable, and whether there may be beneficial effects in females between 3 and 8 years old with Rett syndrome.
- The REVEAL Pediatric Study will test two different dose levels to determine the appropriate dose to test in future clinical trials.

**How many participants will be included in the REVEAL Pediatric Study?**

- There are two parts to the study – Part A and Part B.
  - In Part A, the study will assess the two different dose levels of the investigational gene therapy in **six participants** aged **5 to 8 years old** with Rett syndrome.
    - The first three participants in Part A will receive the first dose level.
    - The next three participants in Part A will receive the second dose level.
  - In Part B, the study will evaluate the dose that is selected from Part A of the study.
    - Part B will include **up to 21 additional participants** and will expand to enroll female children **3 to 8 years old** with Rett syndrome.
- The REVEAL Pediatric Study is currently enrolling Part A of the study.

**Which clinical trial sites are currently enrolling patients in the REVEAL Pediatric Study?**

- A list of clinical trial sites can be found at <https://clinicaltrials.gov/study/NCT06152237>.
- Clinical trial site contact information for the UK will be posted at the same link once available.
- Families who are interested in learning more about the REVEAL Pediatric Study may contact one of the participating clinical trial sites.

If you have any general questions or would like to connect with someone from the Taysha Patient Affairs team, please contact [patientaffairs@tayshagtx.com](mailto:patientaffairs@tayshagtx.com). If your healthcare provider would like to connect with a member of our Taysha Medical Affairs team, please ask them to contact [medinfo@tayshagtx.com](mailto:medinfo@tayshagtx.com).

**We would like to thank the entire Rett community and the Rett patient advocacy groups for your continued partnership. We would also like to acknowledge the individuals and families who choose to participate in research to help better understand the potential of gene therapy for Rett syndrome.**

Sincerely,  
The Taysha Patient Affairs Team

